A novel C5a-derived immunobiotic peptide reduces Streptococcus agalactiae colonization through targeted bacterial killing

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5492-5499

  Cavaco, Courtney K ^a   Patras, Kathryn A ^a   Zlamal, Jaime E ^a   Thoman, Marilyn L ^b   Morgan, Edward L ^b   Sanderson, Sam D ^c   Dorana, Kelly S ^a,d  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; EP67 PEPTIDE; ESTRADIOL; POLYPEPTIDE ANTIBIOTIC AGENT; SEP67 PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE CLEARANCE; DRUG INHIBITION; FEMALE; GROUP B STREPTOCOCCAL INFECTION; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEAL CAVITY; PERITONEUM LAVAGE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS AGALACTIAE; VAGINA; VAGINAL LAVAGE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; COMPLEMENT C5A; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTROPHILS; PEPTIDES; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, INTERLEUKIN-8B; REPRODUCTIVE TRACT INFECTIONS; SPECIES SPECIFICITY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; VAGINA;

EID: 84885901172     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01590-13     Document Type: Article

References (47)

1. Verani JR, Schrag SJ. 2010. Group B streptococcal disease in infants: progress in prevention and continued challenges. Clin. Perinatol. 37:375-392.
2. Maisey HC, Doran KS, Nizet V. 2008. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Rev. Mol. Med. 10:e27. doi:10.1017/S1462399408000811.
3. Doran KS, Nizet V. 2004. Molecular pathogenesis of neonatal group B streptococcal infection: no longer in its infancy. Mol. Microbiol. 54:23-31.
4. Lombard F, Marchandin H, Jacquot A, Cambonie G, Rodiere M, Filleron A. 2012. Streptococcus Agalactiae Late-onset Neonatal Infections: Should Breast Milk Be More Systematically Tested for Bacterial Contamination? Acta Pædiatr. 101:e529-e530.
5. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, Craig AS, Schaffner W, Zansky SM, Gershman K, Stefonek KR, Albanese BA, Zell ER, Schuchat A, Schrag SJ. 2008. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 299:2056-2065.
6. Morgan EL, Morgan BN, Stein EA, Vitrs EL, Thoman ML, Sanderson SD, Phillips JA. 2009. Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design. Vaccine 28:463-469.
7. Vogen SM, Paczkowski NJ, Kirnarsky L, Short A, Whitmore JB, Sherman SA, Taylor SM, Sanderson SD. 2001. Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation. Int. Immunopharmacol. 1:2151-2162.
8. Hung CY, Hurtgen BJ, Bellecourt M, Sanderson SD, Morgan EL, Cole GT. 2012. An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection. Vaccine 30:4681-4690.
9. Sheen TR, Cavaco CK, Ebrahimi CM, Thoman ML, Sanderson SD, Morgan EL, Doran KS. 2011. Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide. Vaccine 30:9-13.
10. Hanke ML, Heim CE, Angle A, Sanderson SD, Kielian T. 2013. Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections. J. Immunol. 190:2159-2168.
11. Phillips JA, Morgan EL, Dong Y, Cole GT, McMahan C, Hung CY, Sanderson SD. 2009. Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone. Bioconjug. Chem. 20:1950-1957.
12. Madoff LC, Michel JL, Kasper DL. 1991. A monoclonal antibody identifies a protective C-protein alpha-antigen epitope in group B streptococci. Infect. Immun. 59:204-210.
13. Wessels MR, Paoletti LC, Rodewald AK, Michon F, DiFabio J, Jennings HJ, Kasper DL. 1993. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 61:4760-4766.
14. Wilkinson HW. 1977. Nontypable group B streptococci isolated from human sources. J. Clin. Microbiol. 6:183-184.
15. Wilson CB, Weaver WM. 1985. Comparative susceptibility of group B streptococci and Staphylococcus aureus to killing by oxygen metabolites. J. Infect. Dis. 152:323-329.
16. Cole JN, Pence MA, von Köckritz-Blickwede M, Hollands A, Gallo RL, Walker MJ, Nizet V. 2010. M protein and hyaluronic acid capsule are essential for in vivo selection of covRS mutations characteristic of invasive serotype M1T1 group A Streptococcus. mBio 1:e00191-10. doi:10.1128/mBio.00191-10.
17. Sullam PM, Valone FH, Mills J. 1987. Mechanisms of platelet aggregation by viridans group streptococci. Infect. Immun. 55:1743-1750.
18. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. 1989. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect. Immun. 57:2037-2042.
19. Highlander SK, Hulten KG, Qin X, Jiang H, Yerrapragada S, Mason EO, Jr, Shang Y, Williams TM, Fortunov RM, Liu Y, Igboeli O, Petrosino J, Tirumalai M, Uzman A, Fox GE, Cardenas AM, Muzny DM, Hemphill L, Ding Y, Dugan S, Blyth PR, Buhay CJ, Dinh HH, Hawes AC, Holder M, Kovar CL, Lee SL, Liu W, Nazareth LV, Wang Q, Zhou J, Kaplan SL, Weinstock GM. 2007. Subtle genetic changes enhance virulence of methicillin resistant and sensitive Staphylococcus aureus.BMC Microbiol. 7:99. doi:10.1186/1471-2180-7-99.
20. van Sorge NM, Zialcita PA, Browne SH, Quach D, Guiney DG, Doran KS. 2011. Penetration and activation of brain endothelium by Salmonella enterica serovar Typhimurium. J. Infect. Dis. 203:401-405.
21. Sheen TR, Jimenez A, Wang NY, Banerjee A, van Sorge NM, Doran KS. 2011. Serine-rich repeat proteins and pili promote Streptococcus agalactiae colonization of the vaginal tract. J. Bacteriol. 193:6834-6842.
22. Patras KA, Wang NY, Fletcher EM, Cavaco CK, Jimenez A, Garg M, Fierer J, Sheen TR, Rajagopal L, Doran KS. 30 January 2013. Group B Streptococcus CovR regulation modulates host immune signalling pathways to promote vaginal colonization. Cell. Microbiol. [Epub ahead of print.]
23. Furr PM, Hetherington CM, Taylor-Robinson D. 1989. The susceptibility of germ-free, oestradiol-treated, mice to Mycoplasma hominis. J. Med. Microbiol. 30:233-236.
24. Cheng Q, Nelson D, Zhu S, Fischetti VA. 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 49:111-117.
25. Sonoda Y, Mukaida N, Wang JB, Shimada-Hiratsuka M, Naito M, Kasahara T, Harada A, Inoue M, Matsushima K. 1998. Physiologic regulation of postovulatory neutrophil migration into vagina in mice by a C-X-C chemokine(s). J. Immunol. 160:6159-6165.
26. Caligioni CS. 2009. Assessing reproductive status/stages in mice. Curr. Protoc. Neurosci. 48:A.4I.1-A.4I.8. doi:10.1002/0471142301.nsa04is48.
27. Poisson DM, Evrard ML, Freneaux C, Vives MI, Mesnard L. 2011. Evaluation of CHROMagar StrepB agar, an aerobic chromogenic medium for prepartum vaginal/rectal group B Streptococcus screening. J. Microbiol. Methods 84:490-491.
28. Nijnik A, Madera L, Ma S, Waldbrook M, Elliott MR, Easton DM, Mayer ML, Mullaly SC, Kindrachuk J, Jenssen H, Hancock RE. 2010. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J. Immunol. 184:2539-2550.
29. Maisey HC, Quach D, Hensler ME, Liu GY, Gallo RL, Nizet V, Doran KS. 2008. A group B streptococcal pilus protein promotes phagocyte resistance and systemic virulence. FASEB J. 22:1715-1724.
30. Sanderson SD, Thoman ML, Kis K, Virts EL, Herrera EB, Widmann S, Sepulveda H, Phillips JA. 2012. Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a. PLoS One 7:e40303. doi:10.1371/journal.pone.0040303.
31. Olson TS, Ley K. 2002. Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283:R7-R28.
32. Svensson M, Yadav M, Holmqvist B, Lutay N, Svanborg C, Godaly G. 2011. Acute pyelonephritis and renal scarring are caused by dysfunctional innate immunity in mCxcr2 heterozygous mice. Kidney Int. 80:1064-1072.
33. Eisele NA, Lee-Lewis H, Besch-Williford C, Brown CR, Anderson DM. 2011. Chemokine receptor CXCR2 mediates bacterial clearance rather than neutrophil recruitment in a murine model of pneumonic plague. Am. J. Pathol. 178:1190-1200.
34. Herbold W, Maus R, Hahn I, Ding N, Srivastava M, Christman JW, Mack M, Reutershan J, Briles DE, Paton JC, Winter C, Welte T, Maus UA. 2010. Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. Infect. Immun. 78:2620-2630.
35. Virta M, Lineri S, Kankaanpaa P, Karp M, Peltonen K, Nuutila J, Lilius EM. 1998. Determination of complement-mediated killing of bacteria by viability staining and bioluminescence. Appl. Environ. Microbiol. 64:515-519.
36. Boulos L, Prevost M, Barbeau B, Coallier J, Desjardins R. 1999. LIVE/ DEAD BacLight: application of a new rapid staining method for direct enumeration of viable and total bacteria in drinking water. J. Microbiol. Methods 37:77-86.
37. Furr PM, Taylor-Robinson D. 1989. Oestradiol-induced infection of the genital tract of female mice by Mycoplasma hominis. J. Gen. Microbiol. 135:2743-2749.
38. Packiam M, Wu H, Veit SJ, Mavrogiorgos N, Jerse AE, Ingalls RR. 2012. Protective role of Toll-like receptor 4 in experimental gonococcal infection of female mice. Mucosal Immunol. 5:19-29.
39. Gilbert NM, Lewis WG, Lewis AL. 2013. Clinical features of bacterial vaginosis in a murine model of vaginal infection with Gardnerella vaginalis. PLoS One 8:e59539. doi:10.1371/journal.pone.0059539.
40. Hickey DK, Patel MV, Fahey JV, Wira CR. 2011. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J. Reprod. Immunol. 88:185-194.
41. Lee J, Cacalano G, Camerato T, Toy K, Moore MW, Wood WI. 1995. Chemokine binding and activities mediated by the mouse IL-8 receptor. J. Immunol. 155:2158-2164.
42. Suzuki A, Urushitani H, Watanabe H, Sato T, Iguchi T, Kobayashi T, Ohta Y. 2007. Comparison of estrogen responsive genes in the mouse uterus, vagina and mammary gland. J. Vet. Med. Sci. 69:725-731.
43. Bohnsack JF, Chang JK, Hill HR. 1993. Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species. Infect. Immun. 61:1421-1426.
44. Taylor SM, Sherman SA, Kirnarsky L, Sanderson SD. 2001. Development of response-selective agonists of human C5a anaphylatoxin: conformational, biological, and therapeutic considerations. Curr. Med. Chem. 8:675-684.
45. Nordahl EA, Rydengard V, Nyberg P, Nitsche DP, Morgelin M, Malmsten M, Bjorck L, Schmidtchen A. 2004. Activation of the complement system generates antibacterial peptides. Proc. Natl. Acad. Sci. U. S. A. 101:16879-16884.
46. Dorschner RA, Lin KH, Murakami M, Gallo RL. 2003. Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. Pediatr. Res. 53:566-572.
47. Wang G, Epand RF, Mishra B, Lushnikova T, Thomas VC, Bayles KW, Epand RM. 2012. Decoding the functional roles of cationic side chains of the major antimicrobial region of human cathelicidin LL-37. Antimicrob. Agents Chemother. 56:845-856.